Halting CKD Progression: From Optimizing Hypertension Management to Newer Agents- April 20, 2022
Claiming Credit for Session
Thank you for attending Halting CKD Progression: From Optimizing Hypertension Management to Newer Agents on April 20, 2022. Once logged in, please click on "Take Course" on the right-hand side and your enrollment will be recorded. You will be prompted to take an evaluation to to claim your credit on the following page.
Target Audience
This activity is intended for all members of the primary care team nationwide in all practice settings, including physicians, advanced practice registered nurses, physician assistants, pharmacists, nurses, dietitians, diabetes educators, and support teams.
Learning Objectives
At the end of this session, participants should be able to:
- Enhance hypertension detection and management in your patients with type 2 diabetes
- Describe the role of SGLT2 inhibitors in minimizing CKD progression in patients with type 2 diabetes
- Use the latest clinical evidence regarding the use of nonsteroidal mineralocorticoid receptor antagonists for treating patients with hypertension and type 2 diabetes
Contact Information
For CME/CNE questions or comments about this activity, please contact Boston University School of Medicine – CME Office at: (617) 358-5005 or cme@bu.edu.
For other questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email info@med-iq.com.
Activity Planners
Linda G. Baer, MSPH, CHCP
Co-Founder & COO
ECHO Diabetes Action Network
Washington, DC
Nicolas Cuttriss, MD, MPH, FAAP
Course Director
Founding Director & CEO
ECHO Diabetes Action Network
Washington, DC
Samantha Gordon, MS
Accreditation Manager
Med-IQ
Baltimore, MD
Sara C. Miller, MS, CPHQ
Vice President, Quality Improvement and Patient Safety
Med-IQ
Baltimore, MD
Julie White, MS, CHCP
Director, Continuing Medical Education Boston University School of Medicine
Boston, MA
Presenting Faculty
Robert Gabbay, MD, PhD, FACP
Endocrinologist
Chief Science & Medical Officer
American Diabetes Association
Arlington, VA
Crystal Gadegbeku, MD, FASN
Nephrologist
Chair of Nephrology, Glickman Urological and Kidney Institute
Cleveland Clinic
Cleveland, OH
American Society of Nephrology Councilor
Katherine R. Tuttle, MD, FASN, FACP, FNKF
Nephrologist & Endocrinologist
Executive Director of Research
Providence Health Care
Professor of Medicine, Division of Nephrology
Co-Principal Investigator
Institute of Translational Health Science
Spokane, WA
Joseph Vassalotti, MD
Nephrologist
Clinical Professor of Medicine
Icahn School of Medicine at Mount Sinai
Chief Medical Officer
National Kidney Foundation
New York, NY
George Thomas, MD
Glickman Urological and Kidney Institute, Cleveland Clinic
Cleveland, OH
Hub Faculty
Nayan Arora, MD
Nephrologist
Clinical Assistant Professor, Medicine
Division of Nephrology
University of Washington
Seattle, WA
Matthew Bouchonville, MD, CDCES
Endocrinologist
Associate Professor, Department of Medicine
University of New Mexico School of Medicine
Medical Director
UNM Diabetes Comprehensive Care Center
UNM Center for Diabetes and Nutrition Education
Albuquerque, NM
Nicolas Cuttriss, MD, MPH, FAAP
Pediatric Endocrinologist
Founding Director & CEO
ECHO Diabetes Action Network
Washington, DC
Phyllisa Deroze, PhD
Patient Advocate
Director of Research
The Diabetes Research Company
Baton Rouge, LA
Korey Hood, PhD
Psychologist
Professor of Pediatrics, Psychiatry and Behavioral Sciences
Staff Psychologist
Stanford University School of Medicine
Palo Alto, CA
Sean Oser, MD, MPH
Primary Care Physician
Associate Professor, Family Medicine
University of Colorado School of Medicine
Denver, CO
Daniel Saltman, MD, FACP
Internal Medicine Physician
Associate Clinical Professor, Department of Medicine
University of Hawaii John A. Burns School of Medicine
Honolulu, Hawaii
Jay H. Shubrook, DO
Primary Care Physician
Professor
Touro University California
Vacaville, CA
Lisa Taylor, DNP, FNP-BC, BC-ADM, CDCES
Nurse Practitioner
Assistant Clinical Professor
University of New Mexico
Albuquerque, NM
Julie Valdes, PharmD, CDCES, CTTS
Pharmacist
Zufall Health Center
Dover, NJ
Kelly Close, MBA
Founder
diaTribe Foundation
San Francisco, CA
Disclosure Statement
In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships with ineligible companies that faculty, planners, authors and anyone who may be in control of content have been mitigated.
Nayan Arora, MD Consulting fees/advisory boards: George Clinical
Matthew Bouchonville, MD, CDCES has no relevant financial relationships to disclose.
Kelly Close, MBA Founder: DiaTribe and Close Concerns, education, advocacy and news service organizations.
Phyllisa Deroze, PhD has no relevant financial relationships to disclose.
Robert Gabbay, MD, PhD, FACP Consulting fees/advisory boards: Lark, Health Reveal, Vida Health, Onduo
Crystal Gadegbeku, MD, FASN Consulting fees/advisory boards: Fresenius Kidney Care. Research Study Advisory Board: Bristol Myers Squibb
Korey Hood, PhD Consulting fees/advisory boards: Cecelia Health, Insulet Corporation, LifeScan Diabetes Institute
Sean Oser, MD , MPH Consulting fees/advisory boards: Dexcom, Inc.
Daniel Saltman, MD, FACP has no relevant financial relationships to disclose.
Jay H. Shubrook, DO Consulting fees/advisory boards: Abbott, AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Eli Lilly and Company, Novo Nordisk
Lisa Taylor, DNP, FNP-BC, BC-ADM, CDCES, CNE Nurse Advisor, has no relevant financial relationships to disclose.
George Thomas, MD Consultant: Up to Date, Contracted research: Boehringer-Ingelheim
Katherine Tuttle, MD, FASN, FACP, FNKF (Presenting faculty) Consulting fees/advisory boards: AstraZeneca, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, Eli Lilly and Company, Gilead Sciences, Inc., Goldfinch Bio, Inc., Novo Nordisk
Contracted research: Bayer HealthCare Pharmaceuticals, Goldfinch Bio, Inc., Travere Therapeutics, Inc.
Julie Valdes, PharmD, CDCES, CTTS has indicated no real or apparent conflicts.
Joseph Vassalotti, MD (Presenting faculty) Consulting fees/advisory boards: Boehringer Ingelheim, Eli Lilly and Company, Renalytix
Accreditor Disclosure
The following planning committee members from Boston University School of Medicine’s Office of Continuing Medical Education have no relevant financial relationships with ineligible companies:
Michael Burk, BS – Senior Program Manager
Ilana Hardesty, MLA - Assistant Director
Catherine Sullivan, MD – CME Accreditation Reviewer
All other faculty /Planning Committee /Administrators and Case Presenters have no relevant financial relationships to disclose.
Disclaimer
THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICALE DUCATION ACTIVITIES ARE INTENDED SOLELY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY AND ECHO DIABETES ACTION NETWORK MAKE NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY OR ECHO DIABETES ACTION NETWORK BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. IN NO EVENT SHOULD INFORMATION IN THE MATERIALS REGARDING LAWS, REGULATIONS, OR LEGAL LIABILITY BE CONSIDERED LEGAL ADVICE OR USED AS A SUBSTITUTE FOR CONSULTING WITH AN ATTORNEY.
Physician Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and the ECHO Diabetes Action Network. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Boston University School of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Accreditation
This educational activity has been provided by Boston University School of Medicine Continuing Nursing Education and jointly-provided by the ECHO Diabetes Action Network.
Boston University School of Medicine Continuing Nursing Education is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
Contact Hours: 1.0
Other Healthcare Professionals
Other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
Boston University Chobanian & Avedisian School of Medicine designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 ANCC
- 1.00 Participation